相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
50.0%
终止
1
50.0%
暂无批准数据
- Exicure (NASDAQ: XCUR) has been granted Australian Patent No. 2018388302 for its innovative combination approach targeting CXCR4 and GPCRx in cancer treatment. - The patent supports Exicure's ongoing Phase 2 clinical trial evaluating GPC-100 and propranolol combination in multiple myeloma patients, aiming to enhance hematopoietic stem cell mobilization. - This intellectual property has already been secured in the United States, Japan, and Taiwan, strengthening Exicure's global patent portfolio for its proprietary co-targeting approach.
• Exicure, Inc. signed an MOU with GPCR Therapeutics to acquire GPCR USA, securing key personnel and clinical pipelines. • The acquisition includes technology transfer for GPCR's CXCR4 inhibitor, currently in Phase 2 trials for multiple myeloma, with a $1-2 billion market. • Exicure plans collaborative R&D with GPCR Therapeutics in immuno-oncology, fibrosis, and obesity, expanding its therapeutic focus. • With recent capital investments totaling $14 million, Exicure aims to advance as a clinical-stage biotech company.
